Complement 3 glomerulopathy
MONDO:0018013A rare primary membranoproliferative glomerulonephritis characterized by complement dysregulation occurring in the fluid phase and in the glomerular microenvironment, which results in prominent complement C3 deposition in kidney biopsy samples.
Also known as: C3 glomerulopathy, C3G, non-Ig-mediated MPGN, non-Ig-mediated membranoproliferative glomerulonephritis, non-immunoglobulin-mediated MPGN, non-immunoglobulin-mediated membranoproliferative glomerulonephritis
27 clinical trials for this condition and its sub-types, 23 tagged with Complement 3 glomerulopathy itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Complement 3 glomerulopathy
-
C3 glomerulonephritis 7 trials
-
Dense deposit disease 5 trials
-
Complement factor H deficiency 0 trials
1 sub-type
-
Experimental shot targets kidney disease at its source
Disease control CompletedThis completed early-stage trial tested an experimental drug called ARO-C3 in 62 healthy volunteers and patients with two types of kidney disease (C3 glomerulopathy and IgA nephropathy). The drug is designed to calm an overactive part of the immune system that can damage the kidn…
Phase 1/2 • Sponsor: Arrowhead Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
New drug aims to stop kidney disease from coming back after transplant
Disease control CompletedThis phase 2 study tested a drug called pegcetacoplan in 13 kidney transplant patients whose original kidney disease (C3G or IC-MPGN) had come back. The goal was to see if the drug could reduce signs of disease activity in the kidney. The study was small and early-stage, so resul…
Phase 2 • Sponsor: Apellis Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Hope for rare kidney patients: new drug shows promise in phase 3 trial
Disease control CompletedThis study tested a drug called pegcetacoplan in 124 adults and teens with two rare kidney diseases (C3G and IC-MPGN). The goal was to see if the drug could reduce protein in the urine, a sign of kidney damage. Participants received either the drug or a placebo twice a week for 2…
Phase 3 • Sponsor: Apellis Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC